title: Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
abstract: More recent techniques to characterize the genetic profile of soft-tissue tumors include the use of gene arrays. Using this technique, Apolipoprotein D (Apo D), a 33-kDa glycoprotein component of high-density lipoprotein, has been found to be highly expressed in dermatofibrosarcoma protuberans. To corroborate these results, we sought to ascertain the utility of Apo D by investigating its sensitivity and specificity in a variety of CD34-positive and CD34-negative cutaneous neoplasms including superficial acral fibromyxoma, sclerotic fibromas, and cellular dermatofibromas. Of interest, we found absence of Apo D expression in all four cases of superficial acral fibromyxoma. Of the remaining CD34-positive lesions, Apo D expression was noted in 35/36 (97%) cases of dermatofibrosarcoma protuberans, 3/5 (60%) giant-cell fibroblastomas, 4/4 (100%) sclerotic fibromas, 8/8 (100%) neurofibromas, and 1/1 (100%) solitary fibrous tumor. Of the CD34-negative lesions, Apo D expression was noted in 2/22 (9%) regular dermatofibroma, 23/45 (51%) cellular dermatofibroma, 10/10 (100%) malignant fibrous histiocytoma, 9/10 (90%) atypical fibroxanthoma, 7/8 (86%) cellular neurothekeoma, 9/9 (100%) malignant melanoma, 8/8 (100%) melanocytic nevi (100%), 0/2 superficial angiomyxoma, 0/15 fibromatosis, 0/1 nodular fasciitis, and 1/2 (50%) desmoplastic fibroblastomas. In summary, our findings indicate that Apo D expression is not specific to dermatofibrosarcoma protuberans. Its principal use as an immunohistochemical adjunct lies in its utility in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Although strong positive staining of Apo D in a markedly atypical fibrohistiocytic lesion is suggestive of atypical fibroxanthoma and/or malignant fibrous histiocytoma, further studies with the inclusion of other atypical spindled cell neoplasms are required to conclusively prove the same.
authors: Department of Pathology, UMass Medical School, Worcester, MA, USA.
authors: Mikhail
authors: M
authors: Lisovsky
authors: Mai P
authors: MP
authors: Hoang
authors: Karen A
authors: KA
authors: Dresser
authors: Payal
authors: P
authors: Kapur
authors: Jag
authors: J
authors: Bhawan
authors: Meera
authors: M
authors: Mahalingam
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis*; D053399:Apolipoproteins D / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D018223:Dermatofibrosarcoma / Q000737:chemistry / Q000175:diagnosis* / Q000276:immunology; D003937:Diagnosis, Differential; D005350:Fibroma / Q000737:chemistry / Q000175:diagnosis* / Q000276:immunology; D005870:Giant Cell Tumors / Q000737:chemistry / Q000175:diagnosis / Q000276:immunology; D018219:Histiocytoma, Benign Fibrous / Q000737:chemistry / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D008545:Melanoma / Q000737:chemistry / Q000175:diagnosis / Q000276:immunology; D009508:Nevus, Pigmented / Q000737:chemistry / Q000175:diagnosis / Q000276:immunology; D015203:Reproducibility of Results; D012878:Skin Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000276:immunology; D014481:United States
chemical_list: D018952:Antigens, CD34; D053399:Apolipoproteins D; D014408:Biomarkers, Tumor